Next Article in Journal
Porifera Lectins: Diversity, Physiological Roles and Biotechnological Potential
Previous Article in Journal
Metabolomic Analysis of Blood Plasma after Oral Administration of N-acetyl-d-Glucosamine in Dogs
Article Menu

Export Article

Open AccessReview
Mar. Drugs 2015, 13(8), 5016-5058; doi:10.3390/md13085016

Eribulin in Cancer Treatment

1
University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242, USA
2
Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY 10461, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Keith B. Glaser
Received: 5 March 2015 / Revised: 18 July 2015 / Accepted: 24 July 2015 / Published: 7 August 2015
View Full-Text   |   Download PDF [951 KB, uploaded 11 August 2015]   |  

Abstract

Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials. View Full-Text
Keywords: breast cancer; EMBRACE; eribulin; E7389; Halichondrin B; Halaven™; microtubule inhibitor; NSC 707389 breast cancer; EMBRACE; eribulin; E7389; Halichondrin B; Halaven™; microtubule inhibitor; NSC 707389
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Swami, U.; Shah, U.; Goel, S. Eribulin in Cancer Treatment. Mar. Drugs 2015, 13, 5016-5058.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top